AU2007211753B2 - Pharmaceutical composition of microspheres for preventing diabetic foot amputation - Google Patents

Pharmaceutical composition of microspheres for preventing diabetic foot amputation Download PDF

Info

Publication number
AU2007211753B2
AU2007211753B2 AU2007211753A AU2007211753A AU2007211753B2 AU 2007211753 B2 AU2007211753 B2 AU 2007211753B2 AU 2007211753 A AU2007211753 A AU 2007211753A AU 2007211753 A AU2007211753 A AU 2007211753A AU 2007211753 B2 AU2007211753 B2 AU 2007211753B2
Authority
AU
Australia
Prior art keywords
microspheres
pharmaceutical composition
treatment
epidermal growth
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007211753A
Other languages
English (en)
Other versions
AU2007211753A1 (en
Inventor
Jorge Amador Berlanga Acosta
Blas Yamir Betancourt Rodriguez
Rolando Paez Meireles
Jose Angel Ramon Hernandez
Vivian Maria Saez Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38185604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007211753(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of AU2007211753A1 publication Critical patent/AU2007211753A1/en
Application granted granted Critical
Publication of AU2007211753B2 publication Critical patent/AU2007211753B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2007211753A 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation Ceased AU2007211753B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU2006-0021 2006-01-31
PCT/CU2007/000002 WO2007087759A2 (es) 2006-01-31 2007-01-29 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Publications (2)

Publication Number Publication Date
AU2007211753A1 AU2007211753A1 (en) 2007-08-09
AU2007211753B2 true AU2007211753B2 (en) 2012-03-01

Family

ID=38185604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007211753A Ceased AU2007211753B2 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation

Country Status (24)

Country Link
US (1) US8741848B2 (enExample)
EP (1) EP1987817B1 (enExample)
JP (1) JP5219841B2 (enExample)
KR (1) KR101401273B1 (enExample)
CN (2) CN103933552A (enExample)
AR (1) AR059234A1 (enExample)
AT (1) ATE437631T1 (enExample)
AU (1) AU2007211753B2 (enExample)
BR (1) BRPI0707395A2 (enExample)
CA (1) CA2640743C (enExample)
CU (1) CU23388B6 (enExample)
CY (1) CY1109513T1 (enExample)
DE (1) DE602007001786D1 (enExample)
DK (1) DK1987817T3 (enExample)
ES (1) ES2330688T3 (enExample)
HK (1) HK1198743A1 (enExample)
MY (1) MY143742A (enExample)
PL (1) PL1987817T3 (enExample)
PT (1) PT1987817E (enExample)
RU (1) RU2426528C2 (enExample)
SG (1) SG169366A1 (enExample)
SI (1) SI1987817T1 (enExample)
WO (1) WO2007087759A2 (enExample)
ZA (1) ZA200806648B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
RU2351334C1 (ru) * 2007-12-04 2009-04-10 Георгий Кимович Золоев Способ лечения хронической ишемии нижних конечностей ii б - iv степени
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너
RU2421221C1 (ru) * 2010-03-22 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения критической ишемии нижних конечностей различного генеза
RU2425675C1 (ru) * 2010-05-25 2011-08-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения больных с нейропатической и нейроишемической формами синдрома "диабетическая стопа"
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN106267163A (zh) * 2015-06-09 2017-01-04 济南博创医药科技有限公司 一种治疗皮肤创伤的药物组合物及其药物制剂
MX389934B (es) * 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
KR102218427B1 (ko) * 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053458A1 (es) * 2001-12-20 2003-07-03 Centro De Ingenieria Genetica Y Biotecnologia Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
KR920700691A (ko) 1989-04-04 1992-08-10 존.에프.맥인티리 상처부위, 절개부위, 찰과상 부위에 치료제의 투여에 대한 리포좀(liposomes)의 용도
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
WO1991001719A1 (en) 1989-08-01 1991-02-21 The University Of Michigan Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
CA2251129A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
CN1126537C (zh) * 1996-05-23 2003-11-05 株式会社三养社 可局部给药,可生物降解和持续释放的用于治疗牙周炎的药物组合物及其制备方法
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
CN101584867A (zh) * 2000-10-31 2009-11-25 瑟莫迪克斯药品公司 提高生物活性分子传递的方法和组合物
AU2003213985A1 (en) 2002-03-12 2003-09-22 Bio-Click Technologies Ltd. Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) * 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO2003053458A1 (es) * 2001-12-20 2003-07-03 Centro De Ingenieria Genetica Y Biotecnologia Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético

Also Published As

Publication number Publication date
PT1987817E (pt) 2009-10-26
EP1987817B1 (en) 2009-07-29
CA2640743C (en) 2012-05-15
BRPI0707395A2 (pt) 2011-05-03
KR20080096804A (ko) 2008-11-03
CA2640743A1 (en) 2007-08-09
US8741848B2 (en) 2014-06-03
DE602007001786D1 (de) 2009-09-10
CN101400338A (zh) 2009-04-01
KR101401273B1 (ko) 2014-05-29
SG169366A1 (en) 2011-03-30
WO2007087759A3 (es) 2007-09-20
CU23388B6 (es) 2009-07-16
HK1198743A1 (en) 2015-06-05
AU2007211753A1 (en) 2007-08-09
DK1987817T3 (da) 2009-11-30
CY1109513T1 (el) 2014-08-13
PL1987817T3 (pl) 2010-01-29
ES2330688T3 (es) 2009-12-14
ATE437631T1 (de) 2009-08-15
AR059234A1 (es) 2008-03-19
MY143742A (en) 2011-07-15
RU2426528C2 (ru) 2011-08-20
CN103933552A (zh) 2014-07-23
WO2007087759A2 (es) 2007-08-09
ZA200806648B (en) 2009-05-27
RU2008135354A (ru) 2010-03-10
EP1987817A2 (en) 2008-11-05
SI1987817T1 (sl) 2009-12-31
US20090220608A1 (en) 2009-09-03
JP5219841B2 (ja) 2013-06-26
JP2009525288A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
AU2007211753B2 (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
Pachuau Recent developments in novel drug delivery systems for wound healing
Maeda et al. Sustained release of human growth hormone (hGH) from collagen film and evaluation of effect on wound healing in db/db mice
Bhatnagar et al. Delivery systems for platelet derived growth factors in wound healing: A review of recent developments and global patent landscape
US20200197286A1 (en) Soluble microneedle for delivering proteins or peptides
US20220331492A1 (en) Composition and method for controlled drug release from a tissue
CN101198348A (zh) 骨形态发生蛋白制剂
AU2006331223B2 (en) Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
Umeki et al. Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release
MX2008009943A (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
HK1130681A (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
JP2001316282A (ja) 生理活性ペプチド含有コラーゲン成形体及びその製法
US20220211683A1 (en) Novel material for skin wound closure and scar prevention
DK1970071T3 (en) USE OF A TOPICAL COMPOSITION CONTAINING epidermal growth factor (Epidermal Growth Factor - EGF) FOR PREVENTION OF DIABETIC FODAMPUTATION
WO1996026716A1 (en) Elcatonin controlled release microsphere formulation for treatment of osteoporosis
Hrynyk Enhanced burn wound healing through controlled and sustained delivery of bioactive insulin from alginate sponge dressings
US20160256565A1 (en) Composite bioabsorbable barrier membranes with sustained dual drug delivery for tissue engineering and guided tissue regeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired